Tissue angiotensin-converting enzyme inhibitors: Are they more effective than serum angiotensin-converting enzyme inhibitors?

Clinical Cardiology

Volumn 28, Issue 12, 2005, Pages 551-555

  Shah, Apurva D ^a   Arora, Rohit R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Heart failure; Myocardial infarction; Serum angiotensin converting enzyme inhibitors; Tissue angiotensin converting enzyme inhibitors

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SERUM DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TISSUE DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; ZINC ION;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; LIPOPHILICITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 28944432558     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960281203     Document Type: Review

References (40)

1. Lonn E, Gerstein HC, Smieja M, Mann JFE, Yusuf S: Mechanisms of cardiovascular risk reduction with ramipril: Insights from HOPE and HOPE substudies. Eur Heart J 2003:5(suppl A);A43-A48
2. Blumberg AL, Denny SE, Marshall GR, Needleman P: Angiotensin (A I, A II, A III) receptor characterization. Correlation of prostaglandin release with peptide degradation. Am J Physiol 1977:232:H305-310
3. Gunther S, Gimbrone MA, Alexander RW: Regulation by angiotensin II of its receptors in resistance blood vessels. Nature 1980;287:230-232
4. Fernandez LA, Twickler J, Mead A: Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145
5. Sayeski PP, Bernstein KE: Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: Looking beyond the heterotrimeric G protein paradigm. J Renin Ang Aldost Syst 2001;2:4-10
6. Ishii K, Takekoshi K, Shibuya S, Kawakami Y, Isobe K, Nakai T: Angiotensin subtype-2 receptor (AT-2) negatively regulates subtype-1 receptor (AT-1) in signal transduction pathways in cultured porcine adrenal medullary chromaffin cells. J Hypertens 2001;19:1991-1999
7. Eguchi S, Inagami T: Signal transduction of angiotensin II type I receptor through receptor tyrosine kinase. Regul Pept 2000:91:13-20
8. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251
9. Iwai N, Inagami T: Identification of two subtypes in the rat type I angiotensin receptor. FEBS Lett 1992;298:257-260
10. Sasamura S, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ: Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 1992;185:253-259
11. Konishi H, Kuroda S, Inada Y, Fujisawa Y: Novel subtype of human angiotensin II type I receptor: cDNA cloning and expression. Biochem Biophys Res Commun 1994;199:467-474
12. Burson JM, Aguilera G, Gross KW, Sigmund CD: Differential expression of angiotensin receptor IA and IB in mouse. Am J Physiol 1994;267:E260-E267
13. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD: Angiotensin II type-I receptor subtype cDNAs: Differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 1992;183:1090-1096
14. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman T: Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995:92:3521-3525
15. Chen XM, Li WG, Yoshida H, Tsuchida S, Nishimura H, Takemoto F, Okubo S, Fogo A, Matsusaka T, Ichikawa I: Targeting deletion of angiotensin type 1b receptor gene in the mouse. Am J Physiol Renal Physiol 1997;41:F299-F304
16. Carey RM, Wang ZQ, Siragy HM: Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-163
17. Catt KJ, Cain MD, Coghlan JP, Zimmet PZ, Cran E, Best JB: Metabolism and blood levels of angiotensin II in normal subjects, renal disease, and es-sential hypertension. Circ Res 1970;26 and 27(suppl II):II-177-II-193
18. Navar LG, Imig JD, Wang CT: Intrarenal production of angiotensin II. Semin Nephrol 1997;17:412-422
19. Campbell DJ, Habener JF: Angiotensin gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 1986;78:31-39
20. Ohkubo HK, Nakayama K, Tanaka T, Nakanishi SS: Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem 1986;261:319-323
21. Bader, M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D: Tissue renin-angiotensin systems: New insight from experimental animal models in hypertension research. J Mol Med 2001;79:76-l02
22. Morimoto S, Sigmund CD: Angiotensin mutant mice: A focus on the brain renin-angiotensin system. Neuropeptides 2002;36:194-200
23. Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-1277
24. Sernia C: A critical appraisal of the intrinsic pancreatic angiotensin-generat-ing system. J Pancreas 2001;2:50-55
25. Liao Y, Husain A: The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11(suppl F):13F-19F
26. Urata H, Ganten D: Cardiac angiotensin II formation: The angiotensin-I converting enzyme and human chymase. Eur Heart J 1993;14(suppl I):177-182
27. Campbell D: Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-6
28. Williams GH: Coverting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1525
29. Leonetti D, Cuspidi C: Choosing the right ACE inhibitor. Drugs 1995;49(4):516-535
30. Wiseman LR, McTavish D: Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in essential hypertension. Drugs 1994;48:72-90
31. White CM: Pharmacologic, pharmacokinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998:18:588-599
32. Leonett G, Cuspidi C: Choosing the right ACE inhibitor: A guide to selection. Drugs 1995;49:516-535
33. Unger T, Gantan D, Lang RE, Schoelkens BA: Persistent tissue converting enzyme inhibition following chronic treatment with HOE 498 and MK 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41
34. Unger T, Ganten D, Moursi M, Ganten D, Herman K, Lang RE: Anti-hypertensive action of the converting enzyme perindopril in spontaneously hypertensive rats. Comparison with enalapril and ramipril. J Cardiovasc Pharmacol 1986;8:276-285
35. Erman A, Winkler J, Chen-Gal B, Rabinov M, Zelykovski A, Tadjer S, Shmueli J, Levi E, Akbary A, Rosenfeld JB: Inhibition of angiotensin converting enzyme in serum and tissue of man. J Hypertens 1991;9:1057-1062
36. Yusut S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-153
37. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
38. Pilote L. Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? Ann Intern Med 2004;141:102-112
39. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard ACG, Pepine CJ. Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-265
40. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L. Lees RS: The Quinipril Ischemic Event (QUIET) Trial: Evaluation of chronic ACE inhibitors therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-1063